Effect of carbamazepine therapy on vitamin D and parathormone in epileptic children.

  title={Effect of carbamazepine therapy on vitamin D and parathormone in epileptic children.},
  author={Abhijit Misra and Anju Aggarwal and O Singh and Sangeeta Sharma},
  journal={Pediatric neurology},
  volume={43 5},

Figures and Tables from this paper

Vitamin D Deficiency in Ambulant Children on Carbamazepine or Sodium Valproate Monotherapy

This study identifies significant risk of vitamin D deficiency in ambulant children with epilepsy on monotherapy with CBZ or VPA as well as age-matched controls from a nearby day-care centre and school.

Effect of carbamazepine therapy on homocysteine, vitamin B12 and folic acid levels in children with epilepsy

6 months of carbamazepine therapy did not cause significant change in serum levels of homocysteine, vitamin B12 and folic acid, and there was no effect of age, sex or dietary pattern on homocy steine levels.

Vitamin D Status in Children on Anticonvulsant Therapy

Serum 25OHD did not differ between patients on cytochrome P450 inducers versus noninducers, neither among the 3 major groups, users of carbamazepine, valproate, and levetiracetam, and the potential risk factors for deficiency.


Antiepileptic drugs negatively effect bone metabolism and increase the risk of osteoporosis, fractures and rickets in children by measuring 25OH vitamin D levels in patients on AEDs.

Analysis of carbamazepine side effects associated with bone metabolism, folate and vitamin B12 serum levels in Isfahan epileptic patients

Investigation of carbamazepine effects on bone density, serum levels of folate, vitamin B12 and other biochemical variables in adult epileptic patients who received CBZ for treatment of epileptic attacks found no correlation between CBZC 0 and homocysteine levels, and further studies related to efficacy and side-effects of CBZ as the most prescribed AEDs in Iranian epileptic population seem to be valuable.

Association of 25-Hydroxyvitamin D Deficiency in Pediatric Epileptic Patients

25-hydroxyvitamin D deficiency was significantly associated with use of carbamazepine and sodium valproate in pediatric epilepsy.

Comparison of 25-hydroxy vitamin D, calcium and alkaline phosphatase levels in epileptic and non-epileptic children.

The results of this study showed that calcium and vitamin D levels were in normal ranges in epileptic and control groups but ALKP levels were significantly higher in epilepsy group which can be a valuable indicator of bone metabolism in these patients.

Vitamin D levels in epileptic children on long-term anticonvulsant therapy

Vitamin D levels in epileptic children with long-term anticonvulsant therapy are lower than that of non-epileptic children, but none had vitamin D deficiency.

Effect of Long-term Carbamazepine Therapy on Bone Health

Patients on long-term antiepileptic therapy, especially with enzyme-inducing agents, could benefit of routine measurement of biochemical markers of bone turnover, and BMD measurement as part of osteoporosis investigation.



Effects of Anticonvulsant Therapy on Vitamin D Status in Children: Prospective Monitoring Study

Evidence is provided that carbamazepine or sodium valproate can cause hypovitaminosis D in children and the effects of seasonality on serum 25-hydroxyvitamin D, parathyroid hormone, and calcium were noticed in patients grouped in classes 0, 2 and 3, as well as in controls.

Adverse effects of antiepileptic drugs on bone mineral density.

Long-term anticonvulsant therapy and vitamin D metabolism in ambulatory pubertal children.

Routine vitamin D supplementation does not appear to be indicated in children on anticonvulsant therapy, and parameters of calcium metabolism were thoroughly examined, indicating that anticonVulsant drugs alter significantly the vitamin D metabolism.

Bone Mineral Status in Pediatric Outpatients on Antiepileptic Drug Monotherapy

Assessment of longitudinally bone mineral status in pediatric outpatients on antiepileptic drug monotherapy found osteopenia was not attributed to a defect in serum active vitamin D production owing to hyperparathyroidism in children on antiespecific drug mon therapy.

Prevalence and treatment of vitamin D deficiency in children on anticonvulsant drugs

In a residential home in southeast England the increased nutritional requirement for vitamin D caused by the administration of anticonvulsants to adolescent epileptic children was of the order of 10 μg cholecalciferol per day.

Effect of vitamin D2 and D3 on bone‐mineral content in carbamazepine‐treated epileptic patients

It is concluded that epileptic patients on carbamazepine monotherapy have normal bone metabolism and the biochemical indices of bone metabolism were virtually unchanged during the treatment period.

A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy

Prevalence of hypocalcemia and elevated serum alkaline phosphatase in patients receiving chronic anticonvulsant therapy.

Residents of an institution for the developmentally disabled in northwest Ohio receiving anticonvulsant therapy for six months or more with phenobarbital or phenytoin or both were studied for the

Evaluation of Bone Mineral Metabolism in Children Receiving Carbamazepine and Valproic Acid

The results suggest that valproic acid and carbamazepine monotherapies have minimal effects on bone mineral metabolism, but routine monitoring of risk and consideration of prophylactic vitamin D supplementation is important.

Does Carbamazepine Treatment Lead to a Need of Extra Vitamin D in some Mentally Retarded Children?

A possibility of hypovitamino‐sis D should be considered in patients on a long‐term carbamazepine therapy, especially if other risks for vitamin D deficiency exist.